Clinuvel Pharmaceuticals Limited Stock Deutsche Boerse AG
Stocks
UR9
AU000000CUV3
Pharmaceuticals
OTC Markets Traded|
Market Closed -
Deutsche Boerse AG
02:04:00 2026-09-24 am EDT
|
5-day change | 1st Jan Change | ||
| 4.900 EUR | 0.00% |
|
0.00% | -30.00% |
| Market Cap | 417M 292M 257M 242M 221M 413M 28.02B 2.89B 1.12B 14.28B 1.1B 1.07B 46.37B | P/E 2027 * |
11.6x | P/E 2028 * | 11x |
|---|---|---|---|---|---|
| Enterprise Value | 133M 92.97M 81.7M 76.97M 70.3M 131M 8.92B 922M 358M 4.55B 349M 342M 14.76B | EV / Sales 2027 * |
1.4x | EV / Sales 2028 * | 0.96x |
| Free-Float |
83.79% | Yield 2027 * |
0.66% | Yield 2028 * | 0.79% |
| Markets | Quality | ||
|---|---|---|---|
Australian S.E.
| CUV | Delayed | |
Tradegate
| UR9 | Real-time | |
|
Boerse Muenchen
| UR9 | Real-time | |
|
OTC Markets
| CLVLF | Delayed | |
|
Berne S.E.
| UR9 | End-of-day quote | |
|
Deutsche Boerse AG
| UR9 | Delayed | |
|
Börse Stuttgart
| UR9 | Delayed |
Last Transcript: Clinuvel Pharmaceuticals Limited
| Current month | -2.97% | ||
| 1 month | -20.97% | ||
| 3 months | -18.33% | ||
| 6 months | -15.52% | ||
| Current year | -30.00% |
| 1 week | 4.9 |  | 4.9 |
| 1 month | 4.9 | | 6.7 |
| Current year | 4.9 | | 7.39 |
| 1 year | 4.9 | | 7.45 |
| 3 years | 4.8 | | 10.94 |
| 5 years | 4.8 | | 26.7 |
| 10 years | 4 | | 27 |
| Manager | Title | Age | Since |
|---|---|---|---|
Philippe Wolgen
CEO | Chief Executive Officer | 63 | 2005-10-31 |
Peter Vaughan
DFI | Director of Finance/CFO | 42 | 2024-06-29 |
| Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Karen Agersborg
BRD | Director/Board Member | - | 2018-01-28 |
Susan Smith
BRD | Director/Board Member | - | 2019-09-22 |
| Chairman | - | 2023-12-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 0.00% | 0.00% | - | - | 294M | |
| -0.72% | +2.76% | +40.17% | -3.49% | 80.07B | |
| +6.98% | +33.79% | +655.41% | +94.84% | 72.7B | |
| -0.07% | +2.70% | -10.41% | -28.96% | 60.45B | |
| -1.80% | -3.05% | -14.24% | +26.38% | 46.24B | |
| +0.14% | +2.81% | +3.67% | +158.04% | 45.97B | |
| -0.51% | +4.79% | +62.49% | -12.15% | 33.62B | |
| -0.16% | -0.25% | +47.20% | +114.18% | 25.26B | |
| -3.48% | +6.06% | +6.80% | +166.49% | 22.95B | |
| -0.82% | -0.77% | +56.61% | +98.36% | 15.44B | |
| Average | -0.71% | +5.23% | +94.19% | +68.19% | 44.74B | |
| Weighted average by Cap. | -0.57% | +6.70% | +134.27% | +52.56% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 94.86M 66.5M 58.44M 55.05M 50.28M 94.02M 6.38B 659M 256M 3.25B 250M 244M 10.56B | 103M 72.22M 63.46M 59.78M 54.6M 102M 6.93B 716M 278M 3.53B 271M 265M 11.47B |
| Net income | 36.02M 25.25M 22.19M 20.9M 19.09M 35.7M 2.42B 250M 97.24M 1.24B 94.81M 92.74M 4.01B | 38.1M 26.71M 23.47M 22.11M 20.19M 37.76M 2.56B 265M 103M 1.31B 100M 98.1M 4.24B |
| Net Debt | -284M -199M -175M -165M -150M -281M -19.1B -1.97B -766M -9.74B -747M -731M -31.6B | -317M -222M -195M -184M -168M -314M -21.34B -2.21B -857M -10.88B -835M -817M -35.32B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-09-24 | €4.900 | 0.00% | 0 |
| 26-09-23 | €4.900 | 0.00% | 0 |
| 26-09-22 | €4.900 | 0.00% | 0 |
| 26-09-21 | €4.900 | 0.00% | 0 |
| 26-09-18 | €4.900 | 0.00% | 0 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- CUV Stock
- UR9 Stock
Select your edition
All financial news and data tailored to specific country editions
